01.07.2008 | Case Reports
A novel EGFR nonsense mutation in a non-small-cell lung cancer (NSCLC) patient who did not derive any clinical benefit with combination chemotherapy and erlotinib
Erschienen in: Clinical and Translational Oncology | Ausgabe 7/2008
Einloggen, um Zugang zu erhalten